Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads prostate cancer scans: could it help doctors stage tumors faster?

NCT ID NCT07707232

Knowledge-focused Sponsor: First Affiliated Hospital of Wenzhou Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tests whether a large language model (a type of AI) can accurately stage prostate cancer by reading Chinese PSMA PET/CT reports. Researchers will compare the AI's staging against expert doctors' assessments using thousands of de-identified reports. The goal is to see if AI can reliably identify cancer stage and uncertainty in the report text, potentially aiding clinical workflows.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Large language model-assisted report annotation workflow
What this could lead to
If successful, this could lead to faster, more consistent staging of prostate cancer from imaging reports, helping doctors make better treatment decisions.
What could go wrong
This is an early, observational study using historical reports, so the model may not perform well in real-world settings or on different types of data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 4,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of male patients aged 18 years or older with clinically diagnosed, pathologically diagnosed, or clinically suspected prostate cancer who underwent PSMA PET/CT as part of routine clinical care. The study will include de-identified Chinese PSMA PET/CT report texts from the First Affiliated Hospital of Wenzhou Medical University, the First Affiliated Hospital of Ningbo University, and Liuzhou People's Hospital, as well as a prospective set of 100 consecutive routine PSMA PET/CT reports from the First Affiliated Hospital of Wenzhou Medical University.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male patients aged 18 years or older. 2. Patients with clinically diagnosed, pathologically diagnosed, or clinically suspected prostate cancer. 3. Patients who underwent PSMA PET/CT for initial staging, recurrence assessment, treatment response evaluation, metastatic assessment, or other clinical purposes during routine care. 4. Complete or basically complete Chinese PSMA PET/CT report text is available, including imaging findings and/or diagnostic impression. 5. The report text contains information that can be used to evaluate at least one target field, such as local prostate lesion, regional lymph nodes, non-regional lymph nodes, bone metastasis, visceral metastasis, or uncertainty expressions. 6. The research data can be de-identified and replaced by a study identification number before analysis. Exclusion Criteria: 1. PSMA PET/CT reports unrelated to prostate cancer, or reports clearly irrelevant to the research task. 2. Reports with severely missing, unreadable, or unavailable main text, imaging findings, or diagnostic impression. 3. Reports that cannot be adequately de-identified or contain residual direct personal identifiers that cannot be safely removed. 4. Duplicate records, repeated exports of the same examination, or records for which the unique report version cannot be confirmed. 5. Reports judged by the research team to be of insufficient quality for manual annotation, model evaluation, or statistical analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.